(Total Views: 279)
Posted On: 05/28/2019 9:31:03 AM
Post# of 154887
Goldman bearish on Gilead, sees 10% downside risk; shares slip 2% premarket https://seekingalpha.com/news/3467096?source=ansh $GILD
"Analyst Terence Flynn cites the looming loss of patent exclusivity for Truvada and Atripla. He also mentions that Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition."
"Analyst Terence Flynn cites the looming loss of patent exclusivity for Truvada and Atripla. He also mentions that Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition."
(0)
(0)
